Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Winston Kung to its Board of Directors, effective August 16, 2024. Mr. Kung, who will also chair the Audit Committee, brings over 20 years of leadership experience in life sciences and investment banking. Currently serving as CFO of Arrivent BioPharma, he has held senior positions at PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, and Amgen.
The company's leadership expressed enthusiasm for Mr. Kung's expertise in pharma industry and capital markets, viewing his appointment as valuable for advancing Corbus' pipeline. Simultaneously, Avery "Chip" Catlin has resigned from the Board and as Audit Committee Chair after serving for over ten years.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ha nominato Winston Kung nel suo Consiglio di Amministrazione, con effetto dal 16 agosto 2024. Il signor Kung, che presiederà anche il Comitato di Revisione, porta con sé oltre 20 anni di esperienza nel settore delle scienze della vita e nella banca d'investimento. Attualmente CFO di Arrivent BioPharma, ha ricoperto ruoli di alto livello presso PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech e Amgen.
La leadership dell'azienda ha espresso entusiasmo per l'expertise del signor Kung nell'industria farmaceutica e nei mercati dei capitali, considerando la sua nomina come preziosa per il progresso della pipeline di Corbus. Contestualmente, Avery "Chip" Catlin si è dimesso dal Consiglio e dalla carica di Presidente del Comitato di Revisione dopo oltre dieci anni di servizio.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ha designado a Winston Kung en su Junta Directiva, con efecto a partir del 16 de agosto de 2024. El Sr. Kung, quien también presidirá el Comité de Auditoría, aporta más de 20 años de experiencia en liderazgo en ciencias de la vida y en el banking de inversión. Actualmente, se desempeña como CFO de Arrivent BioPharma y ha ocupado puestos senior en PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech y Amgen.
El liderazgo de la empresa expresó entusiasmo por la experiencia del Sr. Kung en la industria farmacéutica y en los mercados de capitales, viendo su nombramiento como valioso para avanzar en la pipeline de Corbus. Al mismo tiempo, Avery "Chip" Catlin ha renunciado a la Junta y a la presidencia del Comité de Auditoría después de haber servido durante más de diez años.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)는 윌슨 쿵을 이사회에 임명했습니다, 2024년 8월 16일부터 효력이 발생합니다. 쿵 씨는 감사위원회 의장을 맡고 있으며 생명 과학 및 투자 은행 분야에서 20년 이상의 리더십 경험을 가지고 있습니다. 현재 Arrivent BioPharma의 CFO로 재직 중이며 PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, Amgen에서 고위 직책을 역임했습니다.
회사는 쿵 씨의 제약 산업 및 자본 시장에 대한 전문성에 대해 열정을 표명하며 그의 임명이 Corbus의 파이프라인을 발전시키는 데 소중하다고 보고 있습니다. 동시에, 에이브리 "칩" 캣린은 10년 이상 근무한 후 이사회와 감사위원회 의장직에서 사임했습니다.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) a nommé Winston Kung au sein de son Conseil d'Administration, à compter du 16 août 2024. M. Kung, qui présidera également le Comité d'Audit, apporte plus de 20 ans d'expérience en leadership dans les sciences de la vie et la banque d'investissement. Actuellement CFO d'Arrivent BioPharma, il a occupé des postes de haut niveau chez PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech et Amgen.
La direction de l'entreprise a exprimé son enthousiasme pour l'expertise de M. Kung dans l'industrie pharmaceutique et les marchés des capitaux, considérant sa nomination comme précieuse pour faire avancer le pipeline de Corbus. En même temps, Avery "Chip" Catlin a démissionné du Conseil et de son poste de Président du Comité d'Audit après plus de dix ans de service.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) hat Winston Kung in seinen Vorstand berufen, mit Wirkung zum 16. August 2024. Herr Kung, der auch den Prüfungsausschuss leiten wird, bringt über 20 Jahre Führungserfahrung in den Lebenswissenschaften und im Investmentbanking mit. Derzeit ist er CFO von Arrivent BioPharma und hatte Führungspositionen bei PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech und Amgen inne.
Die Unternehmensführung drückte ihre Begeisterung über Herrn Kungs Expertise in der Pharmaindustrie und den Kapitalmärkten aus und betrachtet seine Berufung als wertvoll für den Fortschritt der Pipeline von Corbus. Gleichzeitig hat Avery "Chip" Catlin nach über zehn Jahren im Dienst aus dem Vorstand und als Vorsitzender des Prüfungsausschusses zurückgetreten.
- Appointment of Winston Kung, an industry veteran with extensive experience in life sciences and investment banking
- Kung's expertise in business development and capital markets could potentially benefit Corbus' pipeline advancement
- Strengthening of the Board with a new Audit Committee chair
- Departure of long-serving Board member Avery Catlin, potentially leading to loss of institutional knowledge
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.
“With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen,” said Alan F. Holmer, Chairman of the Corbus Board of Directors. “We are delighted to welcome someone of Winston’s stature and expertise to our Board and we look forward to his insights and guidance.”
“Winston brings an extensive background in life science industry business development and the capital markets, perspectives that will serve Corbus well as we continue to make progress across our pipeline,” added Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We look forward to working with him as we advance our lead programs to the next phases of their development.”
“Corbus is developing an intriguing asset portfolio in attractive areas of medicine, and has assembled an outstanding leadership team,” said Mr. Kung. “I am delighted to join the Corbus Board at such a pivotal moment in the Company’s development, and look forward to helping realize this portfolio’s full potential."
Mr. Winston Kung is an industry veteran with over 20 years of leadership experience across life sciences and investment banking. Currently, Mr. Kung serves as Chief Financial Officer of Arrivent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics. Prior to Arrivent, Mr. Kung was Chief Financial Officer and Chief Operating Officer at PMV Pharmaceuticals. Prior to joining PMV Pharma, Mr. Kung was Vice President of Business Development and Global Alliances at Celgene, and previously held the position of Chief Business Officer at Celgene Cellular Therapeutics. Before his role at Celgene, Mr. Kung held senior positions at Citigroup’s Global Healthcare Investment Banking group and at Lehman Brothers’ Global Mergers and Acquisition group. Mr. Kung also led multiple transactions as part of Genentech’s and Amgen’s Business and Corporate Development groups. Mr. Kung earned his M.B.A from Harvard Business School and a B.A. in Biology and International Relations from Brown University.
The Company also announced that Avery “Chip” Catlin has resigned from the Board and as Chair of the Audit Committee after serving on the Corbus Board for over ten years. “We wish Chip the best in his future endeavors, and we thank him for his dedication to Corbus during his years of service at Corbus,” stated Mr. Holmer.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
Who is Winston Kung and when was he appointed to Corbus Pharmaceuticals' Board?
What positions will Winston Kung hold at Corbus Pharmaceuticals (CRBP)?
What is Winston Kung's current role outside of Corbus Pharmaceuticals?
Who has resigned from the Corbus Pharmaceuticals (CRBP) Board?
